Amgen's 2025 Growth Strategy: What Does This Mean for Us?

Hey folks, just read this article about Amgen's big plans for 2025. They're pushing hard on obesity drugs and BiTE therapies. As a contractor, I'm always interested in biotech stocks, but this kind of talk can be a double-edged sword. What's everyone's take? Think they'll actually hit those double-digit growth numbers, or is it all hype?

I'm not a big pharma expert, but I've been hearing a lot about MariTide. If it works, that could be a game-changer for obesity treatment. My cousin tried everything, and nothing stuck. But I'm skeptical about these growth projections. They always sound good in conferences. What's the concrete data?

As someone who likes precision in everything, I did a bit of digging. The article mentions momentum in BiTE therapies, but I'm looking for solid clinical trial results. Double-digit growth sounds nice, but it's the pipeline that matters. If MariTide passes Phase 3, then I'd be more confident. Until then, it's just talk.

Restoration work has taught me to read the fine print. Amgen has a solid track record, but biotech is risky. I've seen stocks tank on trial failures. That said, if they're touting this at a conference, they must have something up their sleeve. I might buy a small position, but I'm not betting the house on it.